Thank you! Your request has been received.

A member of our team will reach out to you shortly,
Oops! Something went wrong while submitting the form.
+

Featured

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025

November 3, 2025

Amgen announced that new data from its cardiovascular portfolio, including results from the Phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab)...

Latest Clinical Trial

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025
Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025
Amgen announced that new data from its cardiovascular portfolio, including results from the Phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab)...
November 3, 2025
Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
Genentech announced positive results from the Phase III ALLEGORY study of Gazyva in adults with systemic lupus erythematosus (SLE) on standard therapy...
November 3, 2025
GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis
GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis
Myriad Genetics announced a post-hoc analysis of the PRIME study, revealing that patients with Major Depressive Disorder (MDD) treated based on GeneSi...
November 3, 2025
Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader Programs
Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader Programs
Foghorn Therapeutics announced updates on its Selective ARID1B, CBP, and EP300 degrader programs. The Selective ARID1B degrader selectively binds and ...
October 31, 2025
Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity
Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity
Wave Life Sciences announced positive Activin E target engagement data from the INLIGHT clinical trial of WVE-007, a GalNAc-siRNA, for obesity. The tr...
October 30, 2025
Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis
Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis
AnaptysBio announced positive late-breaking data from its Phase 2b trial of rosnilimab in rheumatoid arthritis (RA). The study demonstrated deepening ...
October 30, 2025
AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo
AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo
AbbVie announced positive topline results from two replicate Phase 3 studies evaluating upadacitinib (RINVOQ®) in adult and adolescent patients with n...
October 30, 2025
TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple Sclerosis
TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple Sclerosis
TG Therapeutics announced the completion of enrollment in the Phase 3 ENHANCE trial, which is evaluating a simplified dosing schedule for BRIUMVI (ubl...
October 29, 2025
Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia Gravis
Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia Gravis
Kyverna Therapeutics announced positive interim Phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis (gMG). The data showed ...
October 29, 2025
Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic Fibrosis
Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic Fibrosis
Sionna Therapeutics announced the presentation of Phase 1 clinical trial data for SION-719 and SION-451, first-in-class NBD1 stabilizers, at the 2025 ...
October 27, 2025
Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF Trial
Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF Trial
Daewoong Pharmaceutical announced that Bersiporocin (DWN12088), its first-in-class drug candidate for idiopathic pulmonary fibrosis (IPF), received a ...
October 27, 2025
Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 Trial
Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 Trial
Innovent Biologics announces positive results from its Phase 3 DREAMS-3 clinical trial of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (G...
October 27, 2025
Xencor Presents Phase 1 Data for XmAb819 in Clear Cell Renal Cell Carcinoma
Xencor Presents Phase 1 Data for XmAb819 in Clear Cell Renal Cell Carcinoma
Xencor announced initial results from the Phase 1 dose-escalation study of XmAb819, a first-in-class ENPP3 x CD3 bispecific T-cell engager, in patient...
October 27, 2025
Cullinan Therapeutics Presents Preclinical Data for CLN-978 Supporting Clinical Development in Autoimmune Diseases at ACR Convergence 2025
Cullinan Therapeutics Presents Preclinical Data for CLN-978 Supporting Clinical Development in Autoimmune Diseases at ACR Convergence 2025
Cullinan Therapeutics presented preclinical data for CLN-978, a CD19xCD3 bispecific T cell engager, at the American College of Rheumatology (ACR) Conv...
October 27, 2025
Lilly's Omvoh (mirikizumab-mrkz) Shows Improvement in Bowel Urgency for Ulcerative Colitis Patients
Lilly's Omvoh (mirikizumab-mrkz) Shows Improvement in Bowel Urgency for Ulcerative Colitis Patients
Eli Lilly and Company announced positive data from the Phase 3b LUCENT-URGE study, demonstrating that Omvoh (mirikizumab-mrkz) significantly improved ...
October 27, 2025
Moderna's Phase 3 CMV Vaccine Trial Fails to Meet Primary Efficacy Endpoint
Moderna's Phase 3 CMV Vaccine Trial Fails to Meet Primary Efficacy Endpoint
Moderna announced that its Phase 3 trial evaluating mRNA-1647, an investigational cytomegalovirus (CMV) vaccine, did not meet its primary efficacy end...
October 23, 2025
Kyverna Therapeutics Announces Conference Call on Interim Phase 2 Data of KYV-101 in Generalized Myasthenia Gravis
Kyverna Therapeutics Announces Conference Call on Interim Phase 2 Data of KYV-101 in Generalized Myasthenia Gravis
Kyverna Therapeutics will host a conference call to discuss interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 in generalized myas...
October 23, 2025
Rozanolixizumab Prevents Congenital Heart Block Recurrence in High-Risk Pregnancy
Rozanolixizumab Prevents Congenital Heart Block Recurrence in High-Risk Pregnancy
NYU Langone Health researchers found that rozanolixizumab, a neonatal Fc receptor (FcRn) inhibitor, can prevent congenital heart block in newborns of ...
October 22, 2025
OS Therapies Announces Positive Survival Data for OST-HER2 in Metastatic Osteosarcoma Subgroups
OS Therapies Announces Positive Survival Data for OST-HER2 in Metastatic Osteosarcoma Subgroups
OS Therapies Inc. announced additional overall and event free survival data from its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected,...
October 22, 2025
AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature Medicine
AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature Medicine
AskBio, a subsidiary of Bayer AG, announced the publication of 12-month data from its Phase 1 trial of AB-1002 gene therapy for congestive heart failu...
October 22, 2025
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Neoadjuvant Primary Uveal Melanoma
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Neoadjuvant Primary Uveal Melanoma
IDEAYA Biosciences announced positive Phase 2 clinical data for darovasertib in the neoadjuvant setting of primary uveal melanoma (UM). The OptimUM-09...
October 21, 2025
Sionna Therapeutics Initiates Phase 2a Trial of SION-719 for Cystic Fibrosis
Sionna Therapeutics Initiates Phase 2a Trial of SION-719 for Cystic Fibrosis
Sionna Therapeutics has initiated the PreciSION CF Phase 2a trial to evaluate SION-719, a novel NBD1 stabilizer, in cystic fibrosis (CF) patients. The...
October 21, 2025
Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025
Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025
Apnimed announced additional data from its Phase 3 SynAIRgy and LunAIRo trials evaluating AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg) for obstructiv...
October 20, 2025
CatalYm Presents Positive Long-Term Phase 1/2a Data for Visugromab in CPI-Refractory Tumors at ESMO 2025
CatalYm Presents Positive Long-Term Phase 1/2a Data for Visugromab in CPI-Refractory Tumors at ESMO 2025
CatalYm announced updated long-term data from its GDFATHER-1/2a trial at ESMO Congress 2025, showcasing the potential of visugromab to reverse resista...
October 20, 2025
Olema Oncology Announces Positive Phase 1b/2 Data of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
Olema Oncology Announces Positive Phase 1b/2 Data of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
Olema Oncology announced updated data from the Phase 1b/2 study of palazestrant in combination with ribociclib in patients with ER+/HER2- advanced or ...
October 20, 2025
Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025
Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025
Disc Medicine will present data from its Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anem...
October 20, 2025
SystImmune and Bristol Myers Squibb Announce Phase I Results of Iza-bren (EGFR x HER3 ADC) in Advanced Solid Tumors
SystImmune and Bristol Myers Squibb Announce Phase I Results of Iza-bren (EGFR x HER3 ADC) in Advanced Solid Tumors
SystImmune and Bristol Myers Squibb announced the first global Phase I results of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjuga...
October 20, 2025
Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer
Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer
Exelixis announced detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in...
October 20, 2025
AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors
AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors
AlphaMedix phase 2 study (ALPHAMEDIX-02) evaluating AlphaMedix (212Pb-DOTAMTATE) in patients with advanced gastroenteropancreatic neuroendocrine tumor...
October 20, 2025
AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia
AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia
AB Science SA announced initial Phase 1 data for the combination of AB8939 with venetoclax for treating refractory or relapsed acute myeloid leukemia ...
October 17, 2025
Praxis Announces Positive Phase 3 Results for Ulixacaltamide in Essential Tremor
Praxis Announces Positive Phase 3 Results for Ulixacaltamide in Essential Tremor
Praxis Precision Medicines announced positive topline results from two pivotal Phase 3 studies (Essential3 program) of ulixacaltamide HCl in patients ...
October 17, 2025
Vor Bio Announces Positive Phase 3 Results of Telitacicept in Systemic Lupus Erythematosus Published in NEJM
Vor Bio Announces Positive Phase 3 Results of Telitacicept in Systemic Lupus Erythematosus Published in NEJM
Vor Bio announces the publication of positive results from a Phase 3 trial in China evaluating telitacicept for systemic lupus erythematosus (SLE) in ...
October 17, 2025
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at AACR-NCI-EORTC Conference
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at AACR-NCI-EORTC Conference
Nuvectis Pharma, Inc. announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and ...
October 17, 2025
Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients
Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients
Aicuris Anti-infective Cures AG announced positive results from its Phase 3 trial (PRIOH-1) of pritelivir for treating refractory Herpes Simplex Virus...
October 16, 2025
Spago Nanomedical Announces Positive Data and Dose Increase Recommendation for 177Lu-SN201 in Phase I/IIa Tumorad-01 Study
Spago Nanomedical Announces Positive Data and Dose Increase Recommendation for 177Lu-SN201 in Phase I/IIa Tumorad-01 Study
Spago Nanomedical announced that the Data Monitoring Committee (DMC) recommended a dose increase in the ongoing Phase I/IIa clinical trial Tumorad-01 ...
October 14, 2025
Gilead and Kite Present New Cancer Data at ESMO 2025, Highlighting Trodelvy's Potential in Metastatic TNBC
Gilead and Kite Present New Cancer Data at ESMO 2025, Highlighting Trodelvy's Potential in Metastatic TNBC
Gilead and Kite will present new data at the ESMO 2025 Congress, showcasing progress in cancer treatment. Key highlights include Phase 3 ASCENT-03 stu...
October 14, 2025
Boehringer and Click Therapeutics present positive Phase III data for CT-155 in Schizophrenia
Boehringer and Click Therapeutics present positive Phase III data for CT-155 in Schizophrenia
Boehringer Ingelheim and Click Therapeutics announced positive results from the Phase III CONVOKE study of CT-155, an investigational prescription dig...
October 14, 2025
Encoded Therapeutics Announces Positive Preclinical Data for Non-Opioid Gene Therapy Candidate for Chronic Pain
Encoded Therapeutics Announces Positive Preclinical Data for Non-Opioid Gene Therapy Candidate for Chronic Pain
Encoded Therapeutics announced preclinical data for its AAV9 microRNA (miRNA) gene therapy candidate targeting SCN9A (NaV1.7) for chronic pain. The da...
October 10, 2025
Taysha Gene Therapies Presents New Data on TSHA-102 for Rett Syndrome at CNS Annual Meeting
Taysha Gene Therapies Presents New Data on TSHA-102 for Rett Syndrome at CNS Annual Meeting
Taysha Gene Therapies announced new supplemental data analysis from Part A of the REVEAL Phase 1/2 trials evaluating TSHA-102 in females with Rett syn...
October 10, 2025
GlyTR Therapeutics Announces Publication of Pan-Cancer Immunotherapy Platform Study in Cell
GlyTR Therapeutics Announces Publication of Pan-Cancer Immunotherapy Platform Study in Cell
GlyTR Therapeutics announced the publication of a study in Cell detailing their Glycan-Dependent T cell Recruiter (GlyTR1 & GlyTR2) therapeutics. Thes...
October 9, 2025
BrYet US Receives Approval to Initiate Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement in Australia
BrYet US Receives Approval to Initiate Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement in Australia
BrYet US, Inc. has received approval to initiate a first-in-human Phase 1/2 clinical trial of ML-016 in Australia. The trial will evaluate the safety,...
October 7, 2025
Prilenia and Ferrer Announce Phase 3 ALS Study of Pridopidine at NEALS 2025
Prilenia and Ferrer Announce Phase 3 ALS Study of Pridopidine at NEALS 2025
Prilenia Therapeutics and Ferrer announced the presentation of their planned pivotal Phase 3 study of pridopidine in Amyotrophic Lateral Sclerosis (AL...
October 7, 2025
Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor Conferences
Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor Conferences
Editas Medicine announced an oral presentation on EDIT-401, a CRISPR gene editing medicine for lowering LDL-cholesterol by upregulating LDLR, at the E...
October 7, 2025
Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease
Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease
Myrtelle Inc. announced encouraging interim results from its Phase 1/2 clinical trial of rAAV-Olig001-ASPA (MYR-101), an investigational gene therapy ...
October 7, 2025
Candel Therapeutics to Present CAN-2409 Data at SITC 2025
Candel Therapeutics to Present CAN-2409 Data at SITC 2025
Candel Therapeutics will present data from its enLIGHTEN™ Discovery Platform and CAN-2409 program in non-small cell lung cancer (NSCLC) at the SITC 20...
October 6, 2025
Invivyd Announces U.S. IND Clearance and FDA Alignment for VYD2311 COVID Prevention Program
Invivyd Announces U.S. IND Clearance and FDA Alignment for VYD2311 COVID Prevention Program
Invivyd announced that the FDA has cleared its IND application and provided feedback to advance its REVOLUTION clinical program for VYD2311, a vaccine...
October 6, 2025
DATROWAY® Improves Overall and Progression-Free Survival in Metastatic Triple-Negative Breast Cancer
DATROWAY® Improves Overall and Progression-Free Survival in Metastatic Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo's DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated statistically significant and clinically meaningful improvements...
October 6, 2025
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program for AML and MDS
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program for AML and MDS
Marker Therapeutics announced the treatment of the first patient in their Phase 1 RAPID study, evaluating MT-401, an off-the-shelf (OTS) multi-antigen...
October 6, 2025
Abivax Announces Positive Results from ABTECT Induction Trials of Obefazimod in Ulcerative Colitis Patients
Abivax Announces Positive Results from ABTECT Induction Trials of Obefazimod in Ulcerative Colitis Patients
Abivax announced late-breaking presentation of 8-Week ABTECT Induction Trial results in participants with and without prior inadequate response to adv...
October 6, 2025
Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027
Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027
Bolt Biotherapeutics announced an update on its Phase 1 dose escalation study of BDC-4182, an ISAC targeting claudin 18.2 for cancer treatment. Initia...
October 2, 2025
EG 427 Announces Positive Topline Results for EG110A in Neurogenic Bladder Patients
EG 427 Announces Positive Topline Results for EG110A in Neurogenic Bladder Patients
EG 427 announced positive initial results from a clinical trial of EG110A, a novel DNA therapy for neurogenic bladder. The study showed an over 88% re...
October 2, 2025
Lisata Therapeutics Announces Positive Preliminary Results from CENDIFOX Trial in Pancreatic Cancer
Lisata Therapeutics Announces Positive Preliminary Results from CENDIFOX Trial in Pancreatic Cancer
Lisata Therapeutics announced encouraging preliminary data from the Phase 1/2a CENDIFOX trial evaluating certepetide in combination with FOLFIRINOX fo...
September 30, 2025
CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack Patients
CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack Patients
CeleCor Therapeutics announced positive topline results from its Phase 3 CeleBrate trial evaluating Disaggpro™ (zalunfiban) for heart attack treatment...
September 24, 2025
OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical Development
OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical Development
OS Therapies Inc. announces its participation in the BioFuture 2025 conference, where it will present an overview of the company with a focus on the c...
September 19, 2025
ONWARD Medical Announces Positive Results for ARC-IM Therapy in Blood Pressure Regulation after Spinal Cord Injury
ONWARD Medical Announces Positive Results for ARC-IM Therapy in Blood Pressure Regulation after Spinal Cord Injury
ONWARD Medical N.V. announced concurrent publications in Nature and Nature Medicine highlighting the benefits of its investigational ARC-IM System for...
September 18, 2025
Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease
Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease
Skyhawk Therapeutics announced positive interim results from its Phase 1 clinical trial of SKY-0515 for Huntington's disease (HD). The trial showed do...
September 18, 2025
Palvella Therapeutics Announces Publication on Rapamycin for Venous Malformations
Palvella Therapeutics Announces Publication on Rapamycin for Venous Malformations
Palvella Therapeutics announces a publication in Lymphatic Research and Biology highlighting advances in understanding venous malformation pathogenesi...
September 18, 2025
Protagonist Announces Clinical Data Presentations for Icotrokinra and PN-881 at EADV 2025 Congress
Protagonist Announces Clinical Data Presentations for Icotrokinra and PN-881 at EADV 2025 Congress
Protagonist Therapeutics announced new clinical data for Icotrokinra in plaque psoriasis from Phase 3 ICONIC-ADVANCE and ICONIC-LEAD studies, being pr...
September 18, 2025
Atossa Therapeutics Seeks Accelerated Approval for Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
Atossa Therapeutics Seeks Accelerated Approval for Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
Atossa Therapeutics has requested a Type C meeting with the FDA to discuss a regulatory strategy for accelerating the development of low-dose (Z)-endo...
September 9, 2025
CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP Study
CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP Study
CASI Pharmaceuticals announced that the Safety Monitoring Committee (SMC) recommended dose escalation of CID-103, an anti-CD38 monoclonal antibody, to...
September 9, 2025
Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101
Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101
Alto Neuroscience announced positive results from an independent, prospective replication study validating theta-band inter-trial coherence (ITC) as a...
September 9, 2025
Positive Phase 1/2 Data for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer
Positive Phase 1/2 Data for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer
IDEAYA Biosciences announced positive data from a Phase 1/2 trial evaluating the combination of IDE397, a MAT2A inhibitor, and Trodelvy (sacituzumab g...
September 9, 2025
Positive Phase 1 Data for IDE849 (SHR-4849) in Small Cell Lung Cancer
Positive Phase 1 Data for IDE849 (SHR-4849) in Small Cell Lung Cancer
IDEAYA Biosciences and Hengrui Pharma presented positive Phase 1 data for IDE849 (SHR-4849), a DLL3-targeting TOP1 antibody-drug conjugate (ADC), at t...
September 8, 2025
Oncolytics Biotech Highlights Pelareorep Efficacy in Metastatic Colorectal Cancer
Oncolytics Biotech Highlights Pelareorep Efficacy in Metastatic Colorectal Cancer
Oncolytics Biotech announced positive clinical and translational data for pelareorep in metastatic colorectal cancer (mCRC). In the REO 022 trial, pe...
September 8, 2025
RYBREVANT® and LAZCLUZE® Combination Prevents Acquired Resistance in First-Line EGFR-Mutated NSCLC
RYBREVANT® and LAZCLUZE® Combination Prevents Acquired Resistance in First-Line EGFR-Mutated NSCLC
Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study demonstrating that the combination of RYBREVANT® (amivantamab-vmjw) and LAZCL...
September 8, 2025
iMDx Enrolls First Patient in GraftAssureDx Clinical Trial
iMDx Enrolls First Patient in GraftAssureDx Clinical Trial
Insight Molecular Diagnostics (iMDx) announced the enrollment of the first patient in its clinical trial for GraftAssureDx, a kitted organ transplant ...
September 8, 2025
Regeneron's Positive Phase 3 Allergy Trials Advance First-in-Class Antibody Blockers
Regeneron's Positive Phase 3 Allergy Trials Advance First-in-Class Antibody Blockers
Regeneron Pharmaceuticals announced positive results from two Phase 3 trials evaluating its first-in-class allergen-blocking antibodies for cat and bi...
September 8, 2025
Rapport Therapeutics to Announce Topline Phase 2a Results for RAP-219 in Focal Onset Seizures
Rapport Therapeutics to Announce Topline Phase 2a Results for RAP-219 in Focal Onset Seizures
Rapport Therapeutics will release topline data from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures on Sep...
September 8, 2025
SCYNEXIS Presents Data on Second-Generation Antifungal SCY-247 at TIMM-12
SCYNEXIS Presents Data on Second-Generation Antifungal SCY-247 at TIMM-12
SCYNEXIS announced multiple presentations at the 12th Congress on Trends in Medical Mycology (TIMM-12) highlighting data on its second-generation anti...
September 5, 2025
Valitor Presents Preclinical Data on VLTR-559 for Wet AMD
Valitor Presents Preclinical Data on VLTR-559 for Wet AMD
Valitor announced positive preclinical data for VLTR-559, a long-acting anti-VEGF drug candidate for wet age-related macular degeneration (AMD). A no...
September 5, 2025
Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's Disease
Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's Disease
Gain Therapeutics announced Australian approval to extend the Phase 1b clinical trial of its drug candidate, GT-02287, for Parkinson's disease by nine...
September 5, 2025
Clene Presents Preclinical Data Supporting CNM-Au8 for Parkinson's Disease
Clene Presents Preclinical Data Supporting CNM-Au8 for Parkinson's Disease
Clene Inc. announced positive preclinical data for CNM-Au8 in treating Parkinson's disease (PD). A novel neuronal model demonstrated CNM-Au8's abilit...
September 5, 2025
AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment
AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment
AL-S Pharma reported positive topline results from its Phase 2 clinical trial of AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1...
September 4, 2025
Sanofi's Amlitelimab Shows Promise in Phase 3 Atopic Dermatitis Study
Sanofi's Amlitelimab Shows Promise in Phase 3 Atopic Dermatitis Study
Sanofi announced positive topline results from the COAST 1 Phase 3 clinical trial of amlitelimab, a monoclonal antibody targeting OX40L, in adults and...
September 4, 2025
Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart Attacks
Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart Attacks
Aspire Biopharma announced positive final results from a clinical trial evaluating its investigational sublingual aspirin product for suspected acute ...
September 4, 2025
Personalis' NeXT Personal MRD Test Shows Superiority in Neoadjuvant Lung Cancer Trial
Personalis' NeXT Personal MRD Test Shows Superiority in Neoadjuvant Lung Cancer Trial
Personalis, Inc. announced positive data from AstraZeneca's phase 3 NeoADAURA trial, demonstrating that their NeXT Personal molecular residual disease...
September 4, 2025
Zymeworks Discontinues ZW171 Clinical Development
Zymeworks Discontinues ZW171 Clinical Development
Zymeworks Inc. announced the discontinuation of clinical development for ZW171, a T cell engager targeting gynecological, thoracic, and digestive syst...
September 2, 2025
Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSD
Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSD
Compass Pathways announced the publication of positive Phase 2 results for their investigational drug COMP360, a synthetic psilocybin, in treating pos...
September 2, 2025
Ascletis to Present ASC30 Data at EASD Annual Meeting
Ascletis to Present ASC30 Data at EASD Annual Meeting
Ascletis Pharma Inc. announced that it will present data from a 28-day multiple ascending dose study of its oral small molecule GLP-1 receptor (GLP-1R...
September 2, 2025
Merck's Enlicitide Decanoate Meets Primary Endpoints in Phase 3 Hypercholesterolemia Trial
Merck's Enlicitide Decanoate Meets Primary Endpoints in Phase 3 Hypercholesterolemia Trial
Merck announced positive topline results from the Phase 3 CORALreef Lipids trial evaluating enlicitide decanoate, an investigational oral PCSK9 inhibi...
September 2, 2025
Olezarsen Shows Significant Reduction in Triglycerides and Acute Pancreatitis in sHTG Patients
Olezarsen Shows Significant Reduction in Triglycerides and Acute Pancreatitis in sHTG Patients
Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyc...
September 2, 2025
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial
Positive results from the BaxHTN Phase III trial demonstrated that baxdrostat, a highly selective aldosterone synthase inhibitor, significantly reduce...
September 1, 2025
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
Alnylam Pharmaceuticals announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) for zilebesiran, an investigational RNAi therapeuti...
September 1, 2025
Roche and Alnylam Advance Zilebesiran into Phase III Cardiovascular Outcomes Trial for Uncontrolled Hypertension
Roche and Alnylam Advance Zilebesiran into Phase III Cardiovascular Outcomes Trial for Uncontrolled Hypertension
Roche and Alnylam announced the initiation of a Phase III cardiovascular outcomes trial (CVOT) for zilebesiran, an RNAi therapeutic, to reduce major a...
September 1, 2025
Merck's VERQUVO (vericiguat) Shows Mixed Results in Chronic Heart Failure Trials
Merck's VERQUVO (vericiguat) Shows Mixed Results in Chronic Heart Failure Trials
Merck announced results from the Phase 3 VICTOR trial and a pooled analysis of VICTOR and VICTORIA trials evaluating VERQUVO (vericiguat) in chronic h...
September 1, 2025
Tourmaline Bio Presents Positive Phase 2 Data for Pacibekitug at ESC Congress 2025
Tourmaline Bio Presents Positive Phase 2 Data for Pacibekitug at ESC Congress 2025
Tourmaline Bio announced positive data from the ongoing Phase 2 TRANQUILITY trial of pacibekitug, a long-acting anti-IL-6 monoclonal antibody, present...
September 1, 2025
Telomir-1: A Novel Epigenetic Therapy Targeting DNA Methylation Pathways
Telomir-1: A Novel Epigenetic Therapy Targeting DNA Methylation Pathways
Telomir Pharmaceuticals announced in vitro data supporting the potential of Telomir-1, a first-in-class epigenetic therapy, in treating cancer, aging,...
August 29, 2025
Zevra Therapeutics to Present Multiple Datasets on MIPLYFFA® (arimoclomol) at ICIEM
Zevra Therapeutics to Present Multiple Datasets on MIPLYFFA® (arimoclomol) at ICIEM
Zevra Therapeutics announced that four posters on MIPLYFFA® (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC), will be present...
August 29, 2025
Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath Analysis
Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath Analysis
Breath Diagnostics announced results from a peer-reviewed clinical study published in The Journal of Thoracic and Cardiovascular Surgery, demonstratin...
August 28, 2025
Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon
Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon
Airiver Medical announced that it has received Investigational Device Exemption (IDE) approval from the FDA to conduct a pivotal clinical trial of its...
August 28, 2025
Actuate Therapeutics' Elraglusib Shows Promising Results in Metastatic Pancreatic Cancer
Actuate Therapeutics' Elraglusib Shows Promising Results in Metastatic Pancreatic Cancer
Actuate Therapeutics announced positive Phase 2 results for elraglusib (elra) in combination with gemcitabine and nab-paclitaxel (GnP) for metastatic ...
August 26, 2025
Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 to Treat ALS
Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 to Treat ALS
Coya Therapeutics announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302, a biologic combination therapy for ...
August 25, 2025
Immuneering and Lilly Partner to Evaluate Atebimetinib and Olomorasib in Phase 2 NSCLC Trial
Immuneering and Lilly Partner to Evaluate Atebimetinib and Olomorasib in Phase 2 NSCLC Trial
Immuneering Corporation announced a clinical supply agreement with Eli Lilly and Company for olomorasib, to be used in combination with Immuneering's ...
August 25, 2025
ITF Therapeutics Announces Positive Long-Term Givinostat Data for Duchenne Muscular Dystrophy
ITF Therapeutics Announces Positive Long-Term Givinostat Data for Duchenne Muscular Dystrophy
ITF Therapeutics announced the publication of positive long-term safety and efficacy data for givinostat in treating Duchenne muscular dystrophy (DMD)...
August 25, 2025
Napo Pharmaceuticals to Meet with FDA Regarding Crofelemer for Ultrarare Pediatric MVID
Napo Pharmaceuticals to Meet with FDA Regarding Crofelemer for Ultrarare Pediatric MVID
Napo Pharmaceuticals, a Jaguar Health family company, plans to meet with the FDA to discuss the clinical development program for crofelemer in treatin...
August 20, 2025
MIRA Pharmaceuticals Completes Phase 1 Trial of Oral Ketamir-2 for Neuropathic Pain
MIRA Pharmaceuticals Completes Phase 1 Trial of Oral Ketamir-2 for Neuropathic Pain
MIRA Pharmaceuticals announced the successful completion of the single ascending dose (SAD) portion of its Phase 1 clinical trial for oral Ketamir-2, ...
August 20, 2025
Rocket Pharmaceuticals' Phase 2 Danon Disease Trial Resumes After FDA Lifts Clinical Hold
Rocket Pharmaceuticals' Phase 2 Danon Disease Trial Resumes After FDA Lifts Clinical Hold
Rocket Pharmaceuticals announced that the FDA has lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease. The hold was lif...
August 20, 2025
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day
IDEAYA Biosciences, Inc. announced the agenda for its 10-year anniversary R&D Day on September 8, 2025. The event will feature presentations on the c...
August 18, 2025
ZyVersa Therapeutics Highlights Data on Kidney Lipotoxicity in Diabetic Kidney Disease
ZyVersa Therapeutics Highlights Data on Kidney Lipotoxicity in Diabetic Kidney Disease
ZyVersa Therapeutics announced data highlighting the critical need for therapies targeting kidney lipotoxicity in diabetic kidney disease (DKD). The ...
August 15, 2025
Largest-Ever Sickle Cell Disease Study Completed, Paving Way for New Treatments
Largest-Ever Sickle Cell Disease Study Completed, Paving Way for New Treatments
Fifty1 AI Labs, in collaboration with The Gates Foundation and leading universities, has completed the largest-ever study of Sickle Cell Disease (SCD)...
August 15, 2025
Boehringer Ingelheim and AimedBio Collaborate to Advance Novel ADC Therapy for Broad Range of Cancers
Boehringer Ingelheim and AimedBio have entered into a global collaboration and licensing agreement to develop a novel antibody-drug conjugate (ADC) th...
October 16, 2025
Biocon Biologics and Civica Expand Partnership to Launch Insulin Glargine for U.S. Diabetes Patients
Biocon Biologics and Civica expand their partnership to include Insulin Glargine, aiming to increase the availability of affordable insulin for the 38...
October 16, 2025
Novo Nordisk to Acquire Akero Therapeutics for up to $5.2 Billion
Akero Therapeutics, a clinical-stage company focused on metabolic diseases, has entered into a definitive agreement to be acquired by Novo Nordisk for...
October 9, 2025
MaxCyte and Moonlight Bio Partner to Advance T Cell Therapies for Solid Tumors
MaxCyte and Moonlight Bio have entered into a Strategic Platform License agreement. Moonlight Bio will utilize MaxCyte’s Flow Electroporation® technol...
October 7, 2025
Elutia Closes BioEnvelope Business Sale to Boston Scientific for $88 Million, Focuses on NXT-41x for Breast Reconstruction Infections
Elutia Inc. has finalized the sale of its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation for $88...
October 2, 2025

Other Clinical Trial Updates

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025

November 3, 2025

Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

November 3, 2025

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis

November 3, 2025

Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader Programs

October 31, 2025

Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity

October 30, 2025

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

October 30, 2025

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

October 30, 2025

TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple Sclerosis

October 29, 2025

Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia Gravis

October 29, 2025

Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic Fibrosis

October 27, 2025

Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF Trial

October 27, 2025

Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 Trial

October 27, 2025

Xencor Presents Phase 1 Data for XmAb819 in Clear Cell Renal Cell Carcinoma

October 27, 2025

Cullinan Therapeutics Presents Preclinical Data for CLN-978 Supporting Clinical Development in Autoimmune Diseases at ACR Convergence 2025

October 27, 2025

Lilly's Omvoh (mirikizumab-mrkz) Shows Improvement in Bowel Urgency for Ulcerative Colitis Patients

October 27, 2025

Moderna's Phase 3 CMV Vaccine Trial Fails to Meet Primary Efficacy Endpoint

October 23, 2025

Kyverna Therapeutics Announces Conference Call on Interim Phase 2 Data of KYV-101 in Generalized Myasthenia Gravis

October 23, 2025

Rozanolixizumab Prevents Congenital Heart Block Recurrence in High-Risk Pregnancy

October 22, 2025

OS Therapies Announces Positive Survival Data for OST-HER2 in Metastatic Osteosarcoma Subgroups

October 22, 2025

AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature Medicine

October 22, 2025

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Neoadjuvant Primary Uveal Melanoma

October 21, 2025

Sionna Therapeutics Initiates Phase 2a Trial of SION-719 for Cystic Fibrosis

October 21, 2025

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025

October 20, 2025

CatalYm Presents Positive Long-Term Phase 1/2a Data for Visugromab in CPI-Refractory Tumors at ESMO 2025

October 20, 2025

Olema Oncology Announces Positive Phase 1b/2 Data of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

October 20, 2025

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025

October 20, 2025

SystImmune and Bristol Myers Squibb Announce Phase I Results of Iza-bren (EGFR x HER3 ADC) in Advanced Solid Tumors

October 20, 2025

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer

October 20, 2025

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors

October 20, 2025

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

October 17, 2025

Praxis Announces Positive Phase 3 Results for Ulixacaltamide in Essential Tremor

October 17, 2025

Vor Bio Announces Positive Phase 3 Results of Telitacicept in Systemic Lupus Erythematosus Published in NEJM

October 17, 2025

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at AACR-NCI-EORTC Conference

October 17, 2025

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

October 16, 2025

Spago Nanomedical Announces Positive Data and Dose Increase Recommendation for 177Lu-SN201 in Phase I/IIa Tumorad-01 Study

October 14, 2025

Gilead and Kite Present New Cancer Data at ESMO 2025, Highlighting Trodelvy's Potential in Metastatic TNBC

October 14, 2025

Boehringer and Click Therapeutics present positive Phase III data for CT-155 in Schizophrenia

October 14, 2025

Encoded Therapeutics Announces Positive Preclinical Data for Non-Opioid Gene Therapy Candidate for Chronic Pain

October 10, 2025

Taysha Gene Therapies Presents New Data on TSHA-102 for Rett Syndrome at CNS Annual Meeting

October 10, 2025

GlyTR Therapeutics Announces Publication of Pan-Cancer Immunotherapy Platform Study in Cell

October 9, 2025

BrYet US Receives Approval to Initiate Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement in Australia

October 7, 2025

Prilenia and Ferrer Announce Phase 3 ALS Study of Pridopidine at NEALS 2025

October 7, 2025

Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor Conferences

October 7, 2025

Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease

October 7, 2025

Candel Therapeutics to Present CAN-2409 Data at SITC 2025

October 6, 2025

Invivyd Announces U.S. IND Clearance and FDA Alignment for VYD2311 COVID Prevention Program

October 6, 2025

DATROWAY® Improves Overall and Progression-Free Survival in Metastatic Triple-Negative Breast Cancer

October 6, 2025

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program for AML and MDS

October 6, 2025

Abivax Announces Positive Results from ABTECT Induction Trials of Obefazimod in Ulcerative Colitis Patients

October 6, 2025

Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027

October 2, 2025

EG 427 Announces Positive Topline Results for EG110A in Neurogenic Bladder Patients

October 2, 2025

Lisata Therapeutics Announces Positive Preliminary Results from CENDIFOX Trial in Pancreatic Cancer

September 30, 2025

CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack Patients

September 24, 2025

OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical Development

September 19, 2025

ONWARD Medical Announces Positive Results for ARC-IM Therapy in Blood Pressure Regulation after Spinal Cord Injury

September 18, 2025

Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease

September 18, 2025

Palvella Therapeutics Announces Publication on Rapamycin for Venous Malformations

September 18, 2025

Protagonist Announces Clinical Data Presentations for Icotrokinra and PN-881 at EADV 2025 Congress

September 18, 2025

Atossa Therapeutics Seeks Accelerated Approval for Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

September 9, 2025

CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP Study

September 9, 2025

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101

September 9, 2025

Positive Phase 1/2 Data for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer

September 9, 2025

Positive Phase 1 Data for IDE849 (SHR-4849) in Small Cell Lung Cancer

September 8, 2025

Oncolytics Biotech Highlights Pelareorep Efficacy in Metastatic Colorectal Cancer

September 8, 2025

RYBREVANT® and LAZCLUZE® Combination Prevents Acquired Resistance in First-Line EGFR-Mutated NSCLC

September 8, 2025

iMDx Enrolls First Patient in GraftAssureDx Clinical Trial

September 8, 2025

Regeneron's Positive Phase 3 Allergy Trials Advance First-in-Class Antibody Blockers

September 8, 2025

Rapport Therapeutics to Announce Topline Phase 2a Results for RAP-219 in Focal Onset Seizures

September 8, 2025

SCYNEXIS Presents Data on Second-Generation Antifungal SCY-247 at TIMM-12

September 5, 2025

Valitor Presents Preclinical Data on VLTR-559 for Wet AMD

September 5, 2025

Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's Disease

September 5, 2025

Clene Presents Preclinical Data Supporting CNM-Au8 for Parkinson's Disease

September 5, 2025

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment

September 4, 2025

Sanofi's Amlitelimab Shows Promise in Phase 3 Atopic Dermatitis Study

September 4, 2025

Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart Attacks

September 4, 2025

Personalis' NeXT Personal MRD Test Shows Superiority in Neoadjuvant Lung Cancer Trial

September 4, 2025

Zymeworks Discontinues ZW171 Clinical Development

September 2, 2025

Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSD

September 2, 2025

Ascletis to Present ASC30 Data at EASD Annual Meeting

September 2, 2025

Merck's Enlicitide Decanoate Meets Primary Endpoints in Phase 3 Hypercholesterolemia Trial

September 2, 2025

Olezarsen Shows Significant Reduction in Triglycerides and Acute Pancreatitis in sHTG Patients

September 2, 2025

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial

September 1, 2025

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

September 1, 2025

Roche and Alnylam Advance Zilebesiran into Phase III Cardiovascular Outcomes Trial for Uncontrolled Hypertension

September 1, 2025

Merck's VERQUVO (vericiguat) Shows Mixed Results in Chronic Heart Failure Trials

September 1, 2025

Tourmaline Bio Presents Positive Phase 2 Data for Pacibekitug at ESC Congress 2025

September 1, 2025

Telomir-1: A Novel Epigenetic Therapy Targeting DNA Methylation Pathways

August 29, 2025

Zevra Therapeutics to Present Multiple Datasets on MIPLYFFA® (arimoclomol) at ICIEM

August 29, 2025

Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath Analysis

August 28, 2025

Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon

August 28, 2025

Actuate Therapeutics' Elraglusib Shows Promising Results in Metastatic Pancreatic Cancer

August 26, 2025

Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 to Treat ALS

August 25, 2025

Immuneering and Lilly Partner to Evaluate Atebimetinib and Olomorasib in Phase 2 NSCLC Trial

August 25, 2025

ITF Therapeutics Announces Positive Long-Term Givinostat Data for Duchenne Muscular Dystrophy

August 25, 2025

Napo Pharmaceuticals to Meet with FDA Regarding Crofelemer for Ultrarare Pediatric MVID

August 20, 2025

MIRA Pharmaceuticals Completes Phase 1 Trial of Oral Ketamir-2 for Neuropathic Pain

August 20, 2025

Rocket Pharmaceuticals' Phase 2 Danon Disease Trial Resumes After FDA Lifts Clinical Hold

August 20, 2025

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day

August 18, 2025

ZyVersa Therapeutics Highlights Data on Kidney Lipotoxicity in Diabetic Kidney Disease

August 15, 2025

Largest-Ever Sickle Cell Disease Study Completed, Paving Way for New Treatments

August 15, 2025

Latest Clinical Trial Updates

No items found.

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

AnaptysBio announced positive late-breaking data from its Phase 2b trial of rosnilimab in rheumatoid arthritis (RA). The study demonstrated deepening ...
October 30, 2025

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025

Amgen announced that new data from its cardiovascular portfolio, including results from the Phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab)...
November 3, 2025

Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

Genentech announced positive results from the Phase III ALLEGORY study of Gazyva in adults with systemic lupus erythematosus (SLE) on standard therapy...
November 3, 2025

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis

Myriad Genetics announced a post-hoc analysis of the PRIME study, revealing that patients with Major Depressive Disorder (MDD) treated based on GeneSi...
November 3, 2025

Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader Programs

Foghorn Therapeutics announced updates on its Selective ARID1B, CBP, and EP300 degrader programs. The Selective ARID1B degrader selectively binds and ...
October 31, 2025

Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity

Wave Life Sciences announced positive Activin E target engagement data from the INLIGHT clinical trial of WVE-007, a GalNAc-siRNA, for obesity. The tr...
October 30, 2025

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

AbbVie announced positive topline results from two replicate Phase 3 studies evaluating upadacitinib (RINVOQ®) in adult and adolescent patients with n...
October 30, 2025

TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple Sclerosis

TG Therapeutics announced the completion of enrollment in the Phase 3 ENHANCE trial, which is evaluating a simplified dosing schedule for BRIUMVI (ubl...
October 29, 2025

Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics announced positive interim Phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis (gMG). The data showed ...
October 29, 2025

Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic Fibrosis

Sionna Therapeutics announced the presentation of Phase 1 clinical trial data for SION-719 and SION-451, first-in-class NBD1 stabilizers, at the 2025 ...
October 27, 2025

Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF Trial

Daewoong Pharmaceutical announced that Bersiporocin (DWN12088), its first-in-class drug candidate for idiopathic pulmonary fibrosis (IPF), received a ...
October 27, 2025

Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 Trial

Innovent Biologics announces positive results from its Phase 3 DREAMS-3 clinical trial of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (G...
October 27, 2025

Xencor Presents Phase 1 Data for XmAb819 in Clear Cell Renal Cell Carcinoma

Xencor announced initial results from the Phase 1 dose-escalation study of XmAb819, a first-in-class ENPP3 x CD3 bispecific T-cell engager, in patient...
October 27, 2025

Cullinan Therapeutics Presents Preclinical Data for CLN-978 Supporting Clinical Development in Autoimmune Diseases at ACR Convergence 2025

Cullinan Therapeutics presented preclinical data for CLN-978, a CD19xCD3 bispecific T cell engager, at the American College of Rheumatology (ACR) Conv...
October 27, 2025

Lilly's Omvoh (mirikizumab-mrkz) Shows Improvement in Bowel Urgency for Ulcerative Colitis Patients

Eli Lilly and Company announced positive data from the Phase 3b LUCENT-URGE study, demonstrating that Omvoh (mirikizumab-mrkz) significantly improved ...
October 27, 2025

Moderna's Phase 3 CMV Vaccine Trial Fails to Meet Primary Efficacy Endpoint

Moderna announced that its Phase 3 trial evaluating mRNA-1647, an investigational cytomegalovirus (CMV) vaccine, did not meet its primary efficacy end...
October 23, 2025

Kyverna Therapeutics Announces Conference Call on Interim Phase 2 Data of KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics will host a conference call to discuss interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 in generalized myas...
October 23, 2025

Rozanolixizumab Prevents Congenital Heart Block Recurrence in High-Risk Pregnancy

NYU Langone Health researchers found that rozanolixizumab, a neonatal Fc receptor (FcRn) inhibitor, can prevent congenital heart block in newborns of ...
October 22, 2025

OS Therapies Announces Positive Survival Data for OST-HER2 in Metastatic Osteosarcoma Subgroups

OS Therapies Inc. announced additional overall and event free survival data from its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected,...
October 22, 2025

AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature Medicine

AskBio, a subsidiary of Bayer AG, announced the publication of 12-month data from its Phase 1 trial of AB-1002 gene therapy for congestive heart failu...
October 22, 2025

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Neoadjuvant Primary Uveal Melanoma

IDEAYA Biosciences announced positive Phase 2 clinical data for darovasertib in the neoadjuvant setting of primary uveal melanoma (UM). The OptimUM-09...
October 21, 2025

Sionna Therapeutics Initiates Phase 2a Trial of SION-719 for Cystic Fibrosis

Sionna Therapeutics has initiated the PreciSION CF Phase 2a trial to evaluate SION-719, a novel NBD1 stabilizer, in cystic fibrosis (CF) patients. The...
October 21, 2025

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025

Apnimed announced additional data from its Phase 3 SynAIRgy and LunAIRo trials evaluating AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg) for obstructiv...
October 20, 2025

CatalYm Presents Positive Long-Term Phase 1/2a Data for Visugromab in CPI-Refractory Tumors at ESMO 2025

CatalYm announced updated long-term data from its GDFATHER-1/2a trial at ESMO Congress 2025, showcasing the potential of visugromab to reverse resista...
October 20, 2025

Olema Oncology Announces Positive Phase 1b/2 Data of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Olema Oncology announced updated data from the Phase 1b/2 study of palazestrant in combination with ribociclib in patients with ER+/HER2- advanced or ...
October 20, 2025

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025

Disc Medicine will present data from its Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anem...
October 20, 2025

SystImmune and Bristol Myers Squibb Announce Phase I Results of Iza-bren (EGFR x HER3 ADC) in Advanced Solid Tumors

SystImmune and Bristol Myers Squibb announced the first global Phase I results of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjuga...
October 20, 2025

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer

Exelixis announced detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in...
October 20, 2025

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors

AlphaMedix phase 2 study (ALPHAMEDIX-02) evaluating AlphaMedix (212Pb-DOTAMTATE) in patients with advanced gastroenteropancreatic neuroendocrine tumor...
October 20, 2025

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

AB Science SA announced initial Phase 1 data for the combination of AB8939 with venetoclax for treating refractory or relapsed acute myeloid leukemia ...
October 17, 2025

Praxis Announces Positive Phase 3 Results for Ulixacaltamide in Essential Tremor

Praxis Precision Medicines announced positive topline results from two pivotal Phase 3 studies (Essential3 program) of ulixacaltamide HCl in patients ...
October 17, 2025

Vor Bio Announces Positive Phase 3 Results of Telitacicept in Systemic Lupus Erythematosus Published in NEJM

Vor Bio announces the publication of positive results from a Phase 3 trial in China evaluating telitacicept for systemic lupus erythematosus (SLE) in ...
October 17, 2025

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at AACR-NCI-EORTC Conference

Nuvectis Pharma, Inc. announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and ...
October 17, 2025

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

Aicuris Anti-infective Cures AG announced positive results from its Phase 3 trial (PRIOH-1) of pritelivir for treating refractory Herpes Simplex Virus...
October 16, 2025

Spago Nanomedical Announces Positive Data and Dose Increase Recommendation for 177Lu-SN201 in Phase I/IIa Tumorad-01 Study

Spago Nanomedical announced that the Data Monitoring Committee (DMC) recommended a dose increase in the ongoing Phase I/IIa clinical trial Tumorad-01 ...
October 14, 2025

Gilead and Kite Present New Cancer Data at ESMO 2025, Highlighting Trodelvy's Potential in Metastatic TNBC

Gilead and Kite will present new data at the ESMO 2025 Congress, showcasing progress in cancer treatment. Key highlights include Phase 3 ASCENT-03 stu...
October 14, 2025

Boehringer and Click Therapeutics present positive Phase III data for CT-155 in Schizophrenia

Boehringer Ingelheim and Click Therapeutics announced positive results from the Phase III CONVOKE study of CT-155, an investigational prescription dig...
October 14, 2025

Encoded Therapeutics Announces Positive Preclinical Data for Non-Opioid Gene Therapy Candidate for Chronic Pain

Encoded Therapeutics announced preclinical data for its AAV9 microRNA (miRNA) gene therapy candidate targeting SCN9A (NaV1.7) for chronic pain. The da...
October 10, 2025

Taysha Gene Therapies Presents New Data on TSHA-102 for Rett Syndrome at CNS Annual Meeting

Taysha Gene Therapies announced new supplemental data analysis from Part A of the REVEAL Phase 1/2 trials evaluating TSHA-102 in females with Rett syn...
October 10, 2025

GlyTR Therapeutics Announces Publication of Pan-Cancer Immunotherapy Platform Study in Cell

GlyTR Therapeutics announced the publication of a study in Cell detailing their Glycan-Dependent T cell Recruiter (GlyTR1 & GlyTR2) therapeutics. Thes...
October 9, 2025

BrYet US Receives Approval to Initiate Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement in Australia

BrYet US, Inc. has received approval to initiate a first-in-human Phase 1/2 clinical trial of ML-016 in Australia. The trial will evaluate the safety,...
October 7, 2025

Prilenia and Ferrer Announce Phase 3 ALS Study of Pridopidine at NEALS 2025

Prilenia Therapeutics and Ferrer announced the presentation of their planned pivotal Phase 3 study of pridopidine in Amyotrophic Lateral Sclerosis (AL...
October 7, 2025

Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor Conferences

Editas Medicine announced an oral presentation on EDIT-401, a CRISPR gene editing medicine for lowering LDL-cholesterol by upregulating LDLR, at the E...
October 7, 2025

Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease

Myrtelle Inc. announced encouraging interim results from its Phase 1/2 clinical trial of rAAV-Olig001-ASPA (MYR-101), an investigational gene therapy ...
October 7, 2025

Candel Therapeutics to Present CAN-2409 Data at SITC 2025

Candel Therapeutics will present data from its enLIGHTEN™ Discovery Platform and CAN-2409 program in non-small cell lung cancer (NSCLC) at the SITC 20...
October 6, 2025

Invivyd Announces U.S. IND Clearance and FDA Alignment for VYD2311 COVID Prevention Program

Invivyd announced that the FDA has cleared its IND application and provided feedback to advance its REVOLUTION clinical program for VYD2311, a vaccine...
October 6, 2025

DATROWAY® Improves Overall and Progression-Free Survival in Metastatic Triple-Negative Breast Cancer

AstraZeneca and Daiichi Sankyo's DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated statistically significant and clinically meaningful improvements...
October 6, 2025

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program for AML and MDS

Marker Therapeutics announced the treatment of the first patient in their Phase 1 RAPID study, evaluating MT-401, an off-the-shelf (OTS) multi-antigen...
October 6, 2025

Abivax Announces Positive Results from ABTECT Induction Trials of Obefazimod in Ulcerative Colitis Patients

Abivax announced late-breaking presentation of 8-Week ABTECT Induction Trial results in participants with and without prior inadequate response to adv...
October 6, 2025

Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027

Bolt Biotherapeutics announced an update on its Phase 1 dose escalation study of BDC-4182, an ISAC targeting claudin 18.2 for cancer treatment. Initia...
October 2, 2025

EG 427 Announces Positive Topline Results for EG110A in Neurogenic Bladder Patients

EG 427 announced positive initial results from a clinical trial of EG110A, a novel DNA therapy for neurogenic bladder. The study showed an over 88% re...
October 2, 2025

Lisata Therapeutics Announces Positive Preliminary Results from CENDIFOX Trial in Pancreatic Cancer

Lisata Therapeutics announced encouraging preliminary data from the Phase 1/2a CENDIFOX trial evaluating certepetide in combination with FOLFIRINOX fo...
September 30, 2025

CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack Patients

CeleCor Therapeutics announced positive topline results from its Phase 3 CeleBrate trial evaluating Disaggpro™ (zalunfiban) for heart attack treatment...
September 24, 2025

OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical Development

OS Therapies Inc. announces its participation in the BioFuture 2025 conference, where it will present an overview of the company with a focus on the c...
September 19, 2025

ONWARD Medical Announces Positive Results for ARC-IM Therapy in Blood Pressure Regulation after Spinal Cord Injury

ONWARD Medical N.V. announced concurrent publications in Nature and Nature Medicine highlighting the benefits of its investigational ARC-IM System for...
September 18, 2025

Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease

Skyhawk Therapeutics announced positive interim results from its Phase 1 clinical trial of SKY-0515 for Huntington's disease (HD). The trial showed do...
September 18, 2025

Palvella Therapeutics Announces Publication on Rapamycin for Venous Malformations

Palvella Therapeutics announces a publication in Lymphatic Research and Biology highlighting advances in understanding venous malformation pathogenesi...
September 18, 2025

Protagonist Announces Clinical Data Presentations for Icotrokinra and PN-881 at EADV 2025 Congress

Protagonist Therapeutics announced new clinical data for Icotrokinra in plaque psoriasis from Phase 3 ICONIC-ADVANCE and ICONIC-LEAD studies, being pr...
September 18, 2025

Atossa Therapeutics Seeks Accelerated Approval for Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Atossa Therapeutics has requested a Type C meeting with the FDA to discuss a regulatory strategy for accelerating the development of low-dose (Z)-endo...
September 9, 2025

CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP Study

CASI Pharmaceuticals announced that the Safety Monitoring Committee (SMC) recommended dose escalation of CID-103, an anti-CD38 monoclonal antibody, to...
September 9, 2025

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101

Alto Neuroscience announced positive results from an independent, prospective replication study validating theta-band inter-trial coherence (ITC) as a...
September 9, 2025

Positive Phase 1/2 Data for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences announced positive data from a Phase 1/2 trial evaluating the combination of IDE397, a MAT2A inhibitor, and Trodelvy (sacituzumab g...
September 9, 2025

Positive Phase 1 Data for IDE849 (SHR-4849) in Small Cell Lung Cancer

IDEAYA Biosciences and Hengrui Pharma presented positive Phase 1 data for IDE849 (SHR-4849), a DLL3-targeting TOP1 antibody-drug conjugate (ADC), at t...
September 8, 2025

Oncolytics Biotech Highlights Pelareorep Efficacy in Metastatic Colorectal Cancer

Oncolytics Biotech announced positive clinical and translational data for pelareorep in metastatic colorectal cancer (mCRC). In the REO 022 trial, pe...
September 8, 2025

RYBREVANT® and LAZCLUZE® Combination Prevents Acquired Resistance in First-Line EGFR-Mutated NSCLC

Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study demonstrating that the combination of RYBREVANT® (amivantamab-vmjw) and LAZCL...
September 8, 2025

iMDx Enrolls First Patient in GraftAssureDx Clinical Trial

Insight Molecular Diagnostics (iMDx) announced the enrollment of the first patient in its clinical trial for GraftAssureDx, a kitted organ transplant ...
September 8, 2025

Regeneron's Positive Phase 3 Allergy Trials Advance First-in-Class Antibody Blockers

Regeneron Pharmaceuticals announced positive results from two Phase 3 trials evaluating its first-in-class allergen-blocking antibodies for cat and bi...
September 8, 2025

Rapport Therapeutics to Announce Topline Phase 2a Results for RAP-219 in Focal Onset Seizures

Rapport Therapeutics will release topline data from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures on Sep...
September 8, 2025

SCYNEXIS Presents Data on Second-Generation Antifungal SCY-247 at TIMM-12

SCYNEXIS announced multiple presentations at the 12th Congress on Trends in Medical Mycology (TIMM-12) highlighting data on its second-generation anti...
September 5, 2025

Valitor Presents Preclinical Data on VLTR-559 for Wet AMD

Valitor announced positive preclinical data for VLTR-559, a long-acting anti-VEGF drug candidate for wet age-related macular degeneration (AMD). A no...
September 5, 2025

Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's Disease

Gain Therapeutics announced Australian approval to extend the Phase 1b clinical trial of its drug candidate, GT-02287, for Parkinson's disease by nine...
September 5, 2025

Clene Presents Preclinical Data Supporting CNM-Au8 for Parkinson's Disease

Clene Inc. announced positive preclinical data for CNM-Au8 in treating Parkinson's disease (PD). A novel neuronal model demonstrated CNM-Au8's abilit...
September 5, 2025

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment

AL-S Pharma reported positive topline results from its Phase 2 clinical trial of AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1...
September 4, 2025

Sanofi's Amlitelimab Shows Promise in Phase 3 Atopic Dermatitis Study

Sanofi announced positive topline results from the COAST 1 Phase 3 clinical trial of amlitelimab, a monoclonal antibody targeting OX40L, in adults and...
September 4, 2025

Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart Attacks

Aspire Biopharma announced positive final results from a clinical trial evaluating its investigational sublingual aspirin product for suspected acute ...
September 4, 2025

Personalis' NeXT Personal MRD Test Shows Superiority in Neoadjuvant Lung Cancer Trial

Personalis, Inc. announced positive data from AstraZeneca's phase 3 NeoADAURA trial, demonstrating that their NeXT Personal molecular residual disease...
September 4, 2025

Zymeworks Discontinues ZW171 Clinical Development

Zymeworks Inc. announced the discontinuation of clinical development for ZW171, a T cell engager targeting gynecological, thoracic, and digestive syst...
September 2, 2025

Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSD

Compass Pathways announced the publication of positive Phase 2 results for their investigational drug COMP360, a synthetic psilocybin, in treating pos...
September 2, 2025

Ascletis to Present ASC30 Data at EASD Annual Meeting

Ascletis Pharma Inc. announced that it will present data from a 28-day multiple ascending dose study of its oral small molecule GLP-1 receptor (GLP-1R...
September 2, 2025

Merck's Enlicitide Decanoate Meets Primary Endpoints in Phase 3 Hypercholesterolemia Trial

Merck announced positive topline results from the Phase 3 CORALreef Lipids trial evaluating enlicitide decanoate, an investigational oral PCSK9 inhibi...
September 2, 2025

Olezarsen Shows Significant Reduction in Triglycerides and Acute Pancreatitis in sHTG Patients

Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyc...
September 2, 2025

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial

Positive results from the BaxHTN Phase III trial demonstrated that baxdrostat, a highly selective aldosterone synthase inhibitor, significantly reduce...
September 1, 2025

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Alnylam Pharmaceuticals announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) for zilebesiran, an investigational RNAi therapeuti...
September 1, 2025

Roche and Alnylam Advance Zilebesiran into Phase III Cardiovascular Outcomes Trial for Uncontrolled Hypertension

Roche and Alnylam announced the initiation of a Phase III cardiovascular outcomes trial (CVOT) for zilebesiran, an RNAi therapeutic, to reduce major a...
September 1, 2025

Merck's VERQUVO (vericiguat) Shows Mixed Results in Chronic Heart Failure Trials

Merck announced results from the Phase 3 VICTOR trial and a pooled analysis of VICTOR and VICTORIA trials evaluating VERQUVO (vericiguat) in chronic h...
September 1, 2025

Tourmaline Bio Presents Positive Phase 2 Data for Pacibekitug at ESC Congress 2025

Tourmaline Bio announced positive data from the ongoing Phase 2 TRANQUILITY trial of pacibekitug, a long-acting anti-IL-6 monoclonal antibody, present...
September 1, 2025

Telomir-1: A Novel Epigenetic Therapy Targeting DNA Methylation Pathways

Telomir Pharmaceuticals announced in vitro data supporting the potential of Telomir-1, a first-in-class epigenetic therapy, in treating cancer, aging,...
August 29, 2025

Zevra Therapeutics to Present Multiple Datasets on MIPLYFFA® (arimoclomol) at ICIEM

Zevra Therapeutics announced that four posters on MIPLYFFA® (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC), will be present...
August 29, 2025

Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath Analysis

Breath Diagnostics announced results from a peer-reviewed clinical study published in The Journal of Thoracic and Cardiovascular Surgery, demonstratin...
August 28, 2025

Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon

Airiver Medical announced that it has received Investigational Device Exemption (IDE) approval from the FDA to conduct a pivotal clinical trial of its...
August 28, 2025

Actuate Therapeutics' Elraglusib Shows Promising Results in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive Phase 2 results for elraglusib (elra) in combination with gemcitabine and nab-paclitaxel (GnP) for metastatic ...
August 26, 2025

Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 to Treat ALS

Coya Therapeutics announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302, a biologic combination therapy for ...
August 25, 2025

Immuneering and Lilly Partner to Evaluate Atebimetinib and Olomorasib in Phase 2 NSCLC Trial

Immuneering Corporation announced a clinical supply agreement with Eli Lilly and Company for olomorasib, to be used in combination with Immuneering's ...
August 25, 2025

ITF Therapeutics Announces Positive Long-Term Givinostat Data for Duchenne Muscular Dystrophy

ITF Therapeutics announced the publication of positive long-term safety and efficacy data for givinostat in treating Duchenne muscular dystrophy (DMD)...
August 25, 2025

Other Clinical Trials Updates

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025

November 4, 2025

Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

November 4, 2025

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis

November 4, 2025

Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader Programs

November 3, 2025

Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity

October 31, 2025

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

October 31, 2025

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

October 31, 2025

TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple Sclerosis

October 30, 2025

Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia Gravis

October 30, 2025

Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic Fibrosis

October 28, 2025

Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF Trial

October 28, 2025

Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 Trial

October 28, 2025

Xencor Presents Phase 1 Data for XmAb819 in Clear Cell Renal Cell Carcinoma

October 28, 2025

Cullinan Therapeutics Presents Preclinical Data for CLN-978 Supporting Clinical Development in Autoimmune Diseases at ACR Convergence 2025

October 28, 2025

Lilly's Omvoh (mirikizumab-mrkz) Shows Improvement in Bowel Urgency for Ulcerative Colitis Patients

October 28, 2025

Moderna's Phase 3 CMV Vaccine Trial Fails to Meet Primary Efficacy Endpoint

October 27, 2025

Kyverna Therapeutics Announces Conference Call on Interim Phase 2 Data of KYV-101 in Generalized Myasthenia Gravis

October 27, 2025

Rozanolixizumab Prevents Congenital Heart Block Recurrence in High-Risk Pregnancy

October 27, 2025

OS Therapies Announces Positive Survival Data for OST-HER2 in Metastatic Osteosarcoma Subgroups

October 27, 2025

AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature Medicine

October 27, 2025

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Neoadjuvant Primary Uveal Melanoma

October 27, 2025

Sionna Therapeutics Initiates Phase 2a Trial of SION-719 for Cystic Fibrosis

October 27, 2025

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025

October 27, 2025

CatalYm Presents Positive Long-Term Phase 1/2a Data for Visugromab in CPI-Refractory Tumors at ESMO 2025

October 27, 2025

Olema Oncology Announces Positive Phase 1b/2 Data of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

October 27, 2025

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025

October 27, 2025

SystImmune and Bristol Myers Squibb Announce Phase I Results of Iza-bren (EGFR x HER3 ADC) in Advanced Solid Tumors

October 27, 2025

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer

October 27, 2025

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors

October 27, 2025

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

October 27, 2025

Praxis Announces Positive Phase 3 Results for Ulixacaltamide in Essential Tremor

October 27, 2025

Vor Bio Announces Positive Phase 3 Results of Telitacicept in Systemic Lupus Erythematosus Published in NEJM

October 27, 2025

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at AACR-NCI-EORTC Conference

October 27, 2025

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

October 27, 2025

Spago Nanomedical Announces Positive Data and Dose Increase Recommendation for 177Lu-SN201 in Phase I/IIa Tumorad-01 Study

October 15, 2025

Gilead and Kite Present New Cancer Data at ESMO 2025, Highlighting Trodelvy's Potential in Metastatic TNBC

October 15, 2025

Boehringer and Click Therapeutics present positive Phase III data for CT-155 in Schizophrenia

October 15, 2025

Encoded Therapeutics Announces Positive Preclinical Data for Non-Opioid Gene Therapy Candidate for Chronic Pain

October 13, 2025

Taysha Gene Therapies Presents New Data on TSHA-102 for Rett Syndrome at CNS Annual Meeting

October 13, 2025

GlyTR Therapeutics Announces Publication of Pan-Cancer Immunotherapy Platform Study in Cell

October 10, 2025

BrYet US Receives Approval to Initiate Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement in Australia

October 8, 2025

Prilenia and Ferrer Announce Phase 3 ALS Study of Pridopidine at NEALS 2025

October 8, 2025

Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor Conferences

October 8, 2025

Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease

October 8, 2025

Candel Therapeutics to Present CAN-2409 Data at SITC 2025

October 8, 2025

Invivyd Announces U.S. IND Clearance and FDA Alignment for VYD2311 COVID Prevention Program

October 8, 2025

DATROWAY® Improves Overall and Progression-Free Survival in Metastatic Triple-Negative Breast Cancer

October 8, 2025

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program for AML and MDS

October 8, 2025

Abivax Announces Positive Results from ABTECT Induction Trials of Obefazimod in Ulcerative Colitis Patients

October 8, 2025

Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027

October 8, 2025

EG 427 Announces Positive Topline Results for EG110A in Neurogenic Bladder Patients

October 8, 2025

Lisata Therapeutics Announces Positive Preliminary Results from CENDIFOX Trial in Pancreatic Cancer

October 1, 2025

CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack Patients

October 1, 2025

OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical Development

October 1, 2025

ONWARD Medical Announces Positive Results for ARC-IM Therapy in Blood Pressure Regulation after Spinal Cord Injury

October 1, 2025

Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease

October 1, 2025

Palvella Therapeutics Announces Publication on Rapamycin for Venous Malformations

October 1, 2025

Protagonist Announces Clinical Data Presentations for Icotrokinra and PN-881 at EADV 2025 Congress

October 1, 2025

Atossa Therapeutics Seeks Accelerated Approval for Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

September 10, 2025

CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP Study

September 10, 2025

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101

September 10, 2025

Positive Phase 1/2 Data for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer

September 10, 2025

Positive Phase 1 Data for IDE849 (SHR-4849) in Small Cell Lung Cancer

September 9, 2025

Oncolytics Biotech Highlights Pelareorep Efficacy in Metastatic Colorectal Cancer

September 9, 2025

RYBREVANT® and LAZCLUZE® Combination Prevents Acquired Resistance in First-Line EGFR-Mutated NSCLC

September 9, 2025

iMDx Enrolls First Patient in GraftAssureDx Clinical Trial

September 9, 2025

Regeneron's Positive Phase 3 Allergy Trials Advance First-in-Class Antibody Blockers

September 9, 2025

Rapport Therapeutics to Announce Topline Phase 2a Results for RAP-219 in Focal Onset Seizures

September 9, 2025

SCYNEXIS Presents Data on Second-Generation Antifungal SCY-247 at TIMM-12

September 9, 2025

Valitor Presents Preclinical Data on VLTR-559 for Wet AMD

September 9, 2025

Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's Disease

September 9, 2025

Clene Presents Preclinical Data Supporting CNM-Au8 for Parkinson's Disease

September 9, 2025

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment

September 5, 2025

Sanofi's Amlitelimab Shows Promise in Phase 3 Atopic Dermatitis Study

September 5, 2025

Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart Attacks

September 5, 2025

Personalis' NeXT Personal MRD Test Shows Superiority in Neoadjuvant Lung Cancer Trial

September 5, 2025

Zymeworks Discontinues ZW171 Clinical Development

September 3, 2025

Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSD

September 3, 2025

Ascletis to Present ASC30 Data at EASD Annual Meeting

September 3, 2025

Merck's Enlicitide Decanoate Meets Primary Endpoints in Phase 3 Hypercholesterolemia Trial

September 3, 2025

Olezarsen Shows Significant Reduction in Triglycerides and Acute Pancreatitis in sHTG Patients

September 3, 2025

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial

September 2, 2025

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

September 2, 2025

Roche and Alnylam Advance Zilebesiran into Phase III Cardiovascular Outcomes Trial for Uncontrolled Hypertension

September 2, 2025

Merck's VERQUVO (vericiguat) Shows Mixed Results in Chronic Heart Failure Trials

September 2, 2025

Tourmaline Bio Presents Positive Phase 2 Data for Pacibekitug at ESC Congress 2025

September 2, 2025

Telomir-1: A Novel Epigenetic Therapy Targeting DNA Methylation Pathways

September 1, 2025

Zevra Therapeutics to Present Multiple Datasets on MIPLYFFA® (arimoclomol) at ICIEM

September 1, 2025

Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath Analysis

September 1, 2025

Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon

September 1, 2025

Actuate Therapeutics' Elraglusib Shows Promising Results in Metastatic Pancreatic Cancer

September 1, 2025

Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 to Treat ALS

August 26, 2025

Immuneering and Lilly Partner to Evaluate Atebimetinib and Olomorasib in Phase 2 NSCLC Trial

August 26, 2025

ITF Therapeutics Announces Positive Long-Term Givinostat Data for Duchenne Muscular Dystrophy

August 26, 2025

Napo Pharmaceuticals to Meet with FDA Regarding Crofelemer for Ultrarare Pediatric MVID

August 21, 2025

MIRA Pharmaceuticals Completes Phase 1 Trial of Oral Ketamir-2 for Neuropathic Pain

August 21, 2025

Rocket Pharmaceuticals' Phase 2 Danon Disease Trial Resumes After FDA Lifts Clinical Hold

August 21, 2025

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day

August 19, 2025

ZyVersa Therapeutics Highlights Data on Kidney Lipotoxicity in Diabetic Kidney Disease

August 18, 2025

Largest-Ever Sickle Cell Disease Study Completed, Paving Way for New Treatments

August 18, 2025

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeInsightsContact UsBlogPricing
One Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
© 2025 Pienomial. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/insights/clinical trial updates